Crossmark

A cancer-unique glycan: de-N-acetyl polysialic acid (dPSA) linked to cell surface nucleolin depends on re-expression of the fetal polysialyltransferase ST8SIA2 gene

Crossref DOI link: https://doi.org/10.1186/s13046-021-02099-y

Published Online: 2021-09-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Moe, Gregory R. https://orcid.org/0000-0003-3410-5065
Steirer, Lindsay M.

Lee, Joshua A.

Shivakumar, Adarsha

Bolanos, Alejandro D.
Funding

Funding for this research was provided by:

Saccharo, Inc.

Children's Hospital Oakland Research Institute

ImpactAssets

Family of Jennifer Leigh Wells
License Information

Text and Data Mining valid from 2021-09-20

Version of Record valid from 2021-09-20
More Information

Article History

Received: 15 February 2021

Accepted: 7 September 2021

First Online: 20 September 2021

Declarations

:

: Not applicable.

: Not applicable.

: G.R.M. is an inventor on several patent applications and issued patents related to therapies and diagnostic applications targeting dPSA. Rights to these inventions have been assigned to UCSF Benioff Children’s Hospital Oakland. G.R.M. is also a founder and stockholder of, and consultant to, Saccharo, Inc., a company focused on developing the therapeutic and diagnostic potential of dPSA.

Document is current

Any future updates will be listed below